Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865836 | 0.87 | IDO1 (0.46) | AOC3LMNAMAPK1TSHRADRA2A | |
| SCHEMBL5865838 | 0.87 | IDO1 (0.46) | AOC3LMNAMAPK1TSHRADRA2A | |
| SCHEMBL5334248 | 0.86 | AOC3 (0.41) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL3077737 | 0.84 | AOC3 (0.47) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL44838 | 0.84 | AOC3 (0.47) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL1669527 | 0.84 | AOC3 (0.47) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL2229096 | 0.80 | AOC3 (0.44) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL9064993 | 0.80 | LMNA (0.45) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL25119768 | 0.78 | TSHR (0.44) | AOC3LMNACES2CES1MAPK1 | |
| SCHEMBL10040021 | 0.78 | LMNA (0.43) | AOC3LMNACES2CES1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | SOUTHERN CALIFORNIA, UNIVERSITY OF | 2004-11-18 | — | — | US | claimed |
| WO-2004063129-A2 | METHODS FOR NUCLEOPHILIC FLUOROMETHYLATION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2004-07-29 | — | — | WO | claimed |
| US-7087789-B2 | Methods for nucleophilic fluoromethylation | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | SOUTHERN CALIFORNIA, UNIVERSITY OF | 2004-11-18 | — | — | US | disclosed |
| WO-2004063129-A2 | METHODS FOR NUCLEOPHILIC FLUOROMETHYLATION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230079-A1 | Methods for nucleophilic fluoromethylation | PHF2, HAO2, GSTM2 | AOC3 141/4885LMNA 4803/4885CES2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.